[1] Garcia-Ortega DY, Martín-Tellez KS, Cuellar-Hubbe M, et al. Desmoid-type fibromatosis[J].Cancers (Basel),2020,12(7):1851. DOI:10.3390/cancers12071851.
[2] Ketelsen D, Hartmann J, Horger M. MR-imaging of aggressive fibromatosis[J].Rofo,2008,180(2):83-86. DOI:10.1055/s-2007-1022688.
[3] Ferenc T, Sygut J, Kopczyński J, et al. Aggressive fibromatosis (desmoid tumors): definition, occurrence, pathology, diagnostic problems, clinical behavior, genetic background[J].Pol J Pathol,2006,57(1):5-15.
[4] Janinis J, Patriki M, Vini L, et al. The pharmacological treatment of aggressive fibromatosis: a systematic review[J].Ann Oncol,2003,14(2):181-190. DOI:10.1093/annonc/mdg064.
[5] Lath C, Khanna PC, Gadewar SB, et al. Inoperable aggressive mesenteric fibromatosis with ureteric fistula. Case report and literature review[J].Eur J Radiol,2006,59(1):117-121. DOI:10.1016/j.ejrad.2005.12.036.
[6] Zhang Z, Shi J, Yang T, et al. Management of aggressive fibromatosis[J].Oncol Lett,2021,21(1):43. DOI:10.3892/ol.2020.12304.
[7] Fiore M, MacNeill A, Gronchi A, et al. Desmoid-type fibromatosis: evolving treatment standards[J].Surg Oncol Clin N Am,2016,25(4):803-826. DOI:10.1016/j.soc.2016.05.010.
|